MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

This study is testing a new drug (an MK2 inhibitor) combined with a standard chemotherapy regimen called mFOLFIRINOX for people with pancreatic cancer that has spread (metastatic). The goal is to see if adding this new drug makes chemotherapy more effective and tolerable. **You may be eligible if...** - You are 18 or older - You have pancreatic ductal adenocarcinoma that has spread or cannot be removed - You have not yet received systemic treatment for advanced/metastatic disease (or you had prior treatment but it was more than 12 months ago) - Your doctor has determined that mFOLFIRINOX is an appropriate option for you - Your liver, kidney, and blood cell counts are at acceptable levels **You may NOT be eligible if...** - You have already received chemotherapy for your advanced disease recently - You have uncontrolled infections or poor organ function - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.